CervoMed's Neflamapimod Shows Brain Volume Improvements in Dementia with Lewy Bodies at AAN 2026

Key Takeaways

• Neflamapimod demonstrated increased basal forebrain volume and functional connectivity in dementia with Lewy bodies patients
• Results suggest disease progression may be reversible in early stages of neurodegeneration, consistent with preclinical studies
• Findings correlate with previously reported blood biomarker improvements, strengthening evidence for neflamapimod’s disease-modifying potential

---

CervoMed Reports Promising Brain Imaging Results for Neflamapimod

CervoMed announced new clinical data at the 2026 American Academy of Neurology (AAN) Annual Meeting demonstrating that neflamapimod increased basal forebrain volume and functional connectivity in patients with dementia with Lewy bodies (DLB). The results provide compelling evidence that the experimental drug may address underlying disease mechanisms rather than just symptoms.

Reversible Disease Progression in Early Stages

The brain imaging findings align with preclinical studies suggesting that neurodegeneration in the basal forebrain—a critical brain region affected in DLB—may be reversible when treated in early disease stages. This represents a significant advancement in understanding how neflamapimod works at the cellular level.

The data also correlates with previously reported improvements in blood biomarkers of neurodegenerative disease activity, providing multiple lines of evidence supporting neflamapimod’s potential as a disease-modifying therapy.

Addressing Critical Unmet Need in DLB

Dementia with Lewy bodies is the second most common form of progressive dementia after Alzheimer’s disease, affecting approximately 1.4 million Americans. Current treatments only manage symptoms without slowing disease progression, making neflamapimod’s potential disease-modifying effects particularly significant for patients and families.

The basal forebrain plays a crucial role in cognitive function, and its deterioration contributes to the memory problems, attention deficits, and other cognitive symptoms characteristic of DLB. Neflamapimod’s ability to improve both volume and connectivity in this region suggests it may help preserve or restore cognitive abilities.

Market Implications and Next Steps

These positive results strengthen CervoMed’s position in the competitive neurodegeneration market and may attract additional investment or partnership opportunities. The convergence of brain imaging improvements with biomarker data provides robust evidence that could support regulatory discussions and future clinical trial design.

The company has not yet announced specific timelines for advancing neflamapimod through later-stage clinical development, but these encouraging results are likely to accelerate planning for pivotal studies in DLB patients.

---

Frequently Asked Questions

What does this mean for patients with dementia with Lewy bodies?

The results suggest neflamapimod may actually slow or reverse brain deterioration rather than just treating symptoms, potentially offering the first disease-modifying treatment for DLB patients.

When will neflamapimod be available to patients?

The drug is still in clinical trials and not yet approved. CervoMed will need to complete additional studies and obtain regulatory approval before neflamapimod becomes commercially available.

How does neflamapimod compare to existing DLB treatments?

Current DLB treatments only manage symptoms temporarily. Neflamapimod appears to target underlying disease mechanisms and may actually improve brain structure and function, representing a fundamentally different approach.